Despite hitting the market more than a year ago with steep discounts, biosimilars for AbbVie’s blockbuster arthritis treatment Humira (adalimumab) have managed to take only 4% of the market share away from the branded reference product, according to the latest quarterly report from Samsung Bioepis.
Tag Archive for: Yuflyma
Consumer healthcare brand CVS Health on Wednesday launched Cordavis, a wholly owned subsidiary focused on the growing U.S. biosimilars market that will work directly with manufacturers.
The copycat drug was launched at about a 5% discount, adding to the growing competition for the blockbuster rheumatoid arthritis drug in the U.S.